Bayer invests in U.S. growth to get it through its big transitions

Carly Helfand Plenty of Bayer's peers are focusing their expansion efforts outside the U.S., on emerging markets with more growth potential. But not the German pharma. Instead, ...

U.K. keeps funding for clinical research sites flat through to 2022

Nick Paul Taylor The United Kingdom government is to pump £112 million ($ 160 million) into a network of clinical research facilities from 2017 to 2022. Officials see the investment ...

BioLineRx joins immuno-oncology scrum through Keytruda combo deal

Nick Paul Taylor BioLineRx has become the latest company to stake its claim for a spot on the burgeoning roster of immuno-oncology combinations. The small biotech is aiming to muscle ...

Adamas soars as its Parkinson’s drug comes through in Phase III

Damian Garde Adamas Pharmaceuticals' lead drug met its main goals of reducing side effects related to Parkinson's disease treatment in a late-stage trial, the company said, ...

Boehringer Ingelheim picks family member to lead it through tough times

Eric Palmer Boehringer Ingelheim has picked a member of the founding family as CEO for the first time in a quarter of a century to help it through its lean times. The drugmaker announced ...

Novo Nordisk’s first foray into obesity comes through in Phase III

Damian Garde In new late-stage data, Novo Nordisk's inaugural obesity drug spurred statistically significant weight loss compared to placebo, bolstering the company's case as ...

Cyramza, key to Lilly’s oncology hopes, comes through in colorectal cancer

Damian Garde Eli Lilly's Cyramza (ramucirumab) met its primary endpoint in a study on metastatic colorectal cancer, good news for a key cog in the drugmaker's plans to capitalize ...

Mapp’s Ebola treatment comes through in a preclinical study

Damian Garde Tiny Mapp Biopharmaceutical's much-scrutinized Ebola treatment proved 100% effective in animal studies, the company said, stoking hopes that the investigational therapy ...

AstraZeneca’s new antibiotic comes through in Phase III

Damian Garde AstraZeneca's antibiotic combination treatment beat out standard meropenem in treating complicated infections, the company said, setting the table for a near-term shot ...

Naurex picks up $25M to get its depression drugs through PhII

Damian Garde Evanston, IL's Naurex nailed down another $ 25 million in venture funding to accelerate its two-pronged depression program, posting positive mid-stage results for ...

Walgreens to Provide Employer-Sponsored Health Insurance Through Aon Hewitt Corporate Health Exchange in 2014

barbara.lempert Program will continue providing value-based pharmacy benefit for employees by excluding prescriptions from plan deductibles to improve medication adherence DEERFIELD, ...

Industry Voices: Researching ALS through new eyes–Why data science will foster life science breakthroughs

Alok Saboo An innovative new approach, drawing on the disciplines of both medical science and data science, offers the promise of an unprecedented breakthrough in the search for a cure ...
© 2018 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS